Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1988 2
1990 3
1991 2
1992 3
1993 3
1994 7
1995 4
1996 3
1997 2
1998 3
1999 3
2000 3
2001 3
2002 2
2003 2
2004 5
2005 4
2006 5
2007 9
2008 7
2009 3
2010 4
2011 5
2012 7
2013 7
2014 8
2015 12
2016 6
2017 13
2018 13
2019 9
2020 8
2021 8
2022 11
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Wiviott SD, et al. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415602 Clinical Trial.
Therapy of Type 1 Diabetes.
Haak T, Gölz S, Fritsche A, Füchtenbusch M, Siegmund T, Schnellbächer E, Klein HH, Uebel T, Droßel D. Haak T, et al. Exp Clin Endocrinol Diabetes. 2019 Dec;127(S 01):S27-S38. doi: 10.1055/a-0984-5696. Epub 2019 Dec 20. Exp Clin Endocrinol Diabetes. 2019. PMID: 31860925 Free article. Review. No abstract available.
Diabetes and Pregnancy.
Hummel M, Füchtenbusch M, Battefeld W, Bührer C, Groten T, Haak T, Kainer F, Kautzky-Willer A, Lechner A, Meissner T, Nagel-Reuper C, Schäfer-Graf U, Siegmund T. Hummel M, et al. Among authors: haak t. Exp Clin Endocrinol Diabetes. 2023 Feb;131(1-02):4-12. doi: 10.1055/a-1946-3648. Epub 2023 Jan 10. Exp Clin Endocrinol Diabetes. 2023. PMID: 36626920 No abstract available.
Telmisartan, ramipril, or both in patients at high risk for vascular events.
ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. ONTARGET Investigators, et al. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31. N Engl J Med. 2008. PMID: 18378520 Free article. Clinical Trial.
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, et al. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29. Lancet. 2008. PMID: 18757085 Clinical Trial.
Fundamentals of Diabetes Management.
Kulzer B, Aberle J, Haak T, Kaltheuner M, Kröger J, Landgraf R, Kellerer M. Kulzer B, et al. Among authors: haak t. Exp Clin Endocrinol Diabetes. 2022 Sep;130(S 01):S9-S18. doi: 10.1055/a-1624-5080. Epub 2022 Apr 29. Exp Clin Endocrinol Diabetes. 2022. PMID: 35488178 No abstract available.
182 results